The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...

U is a selective estrogen receptor degrader (Selective estrogen receptor degraders (SERDs)) that is being evaluated as a once-daily oral treatment for patients with estrogen receptor-positive (ER+ ...

This is a new kind of oral selective estrogen receptor degrader (SERD), used to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast ...

Aromatase inhibitors (AI) are among the most widely used therapies in the treatment of breast tumors expressing estrogen receptor α (ERα). Alone or in combination with other agents, they are the ...

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive ...

The EMBER-3 study introduced imlunestrant, an oral selective estrogen receptor degrader (SERD), as a potential treatment for hormone receptor–positive, HER2-negative metastatic breast cancer ...

DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight” report provides comprehensive insights about 100+ companies and ...

Paolo Tarantino, MD, PhD, discusses the approval of the oral therapy elacestrant for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations.

Morgan Stanley analyst Michael Ulz has maintained their neutral stance on ZNTL stock, giving a Hold rating yesterday.Invest with Confidence: ...

In a report released on January 29, Andrew Berens from Leerink Partners maintained a Hold rating on Zentalis Pharmaceuticals (ZNTL – Research ...

Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies ...

Live webcasts of these presentations will be available in the Events and Presentations section of Olema’s investor relations website at ir.olema.com. The webcasts will be archived for at least 30 days ...